胰岛素联合治疗的新选择--基础胰岛素+GLP-1受体激动剂

摘要

糖尿病严重危害人类健康，其治疗也受到越来越多的重视。基础胰岛素可以增加外周对葡萄糖的利用，减少肝糖输出，有效控制空腹血糖，但可能增加体重、加重胰岛素抵抗。而GLP-1受体激动剂类药物可促进和恢复内源胰岛素的分泌，抑制胰高血糖素分泌，同时延缓胃排空、抑制食欲，从而减轻体重、改善胰岛素抵抗。GLP-1主要降低餐后血糖，与餐时胰岛素相比，明显降低了低血糖风险。基础胰岛素与GLP-1受体激动剂联合应用可扬长避短，发挥协同互补的作用，成为2型糖尿病治疗的新选择。%Diabetes cause serious damage to human health, thus the treatment has become more and more important. Basal insulin can increase the glucose utilization in peripheral insulin, reduce glycogen output, effectively control blood sugar on an empty stomach, but may increase the body weight, increase insulin resistance. And glp-1 agonist drugs can promote and restore endogenous insulin secretion, suppress glucagon secretion, at the same time delay gastric emptying, suppress appetite, and weight loss, and improve insulin resistance. Glp-1 may reduce postprandial blood glucose; insulin when compared to the meal significantly reduces the risk of hypoglycemia. Insulin and combined glp-1 agonists can foster strengths and circumvent weaknesses, thus play an important role in the treatment of type 2 diabetes.